<div class="csl-bib-body">
<div class="csl-entry">Weiss, V., Kuban Petr, Lado Sara, Steininger, C., & Breyer, M.-K. (2026, September 22). <i>Exhaled breath condensate (EBC) analysis via gas-phase electrophoresis (nES GEMMA instrumentation)</i> [Conference Presentation]. Chemie Tage 2026, Krems, Austria. http://hdl.handle.net/20.500.12708/231237</div>
</div>
-
dc.identifier.uri
http://hdl.handle.net/20.500.12708/231237
-
dc.description.abstract
Retrieving a representative, unbiased sample directly and non-invasively from the lung of a patient followed by its analyis is an attractive strategy to gain information on the health status of an individual. In this respect we focussed on collection of exhaled breath condensate (EBC) in combination with gas-phase electrophoresis on a nano electrospray gas-phase electrophoretic mobility molecular analyzer (nES GEMMA). This latter instrument enables characterization of (bio-)nanomaterials in their native state in respect to their size, size distribution and particle number concentration [1] in accordance with recommendations of the EC for nanomaterial characterization. In the first part of our study we worked with a pool of n=15 volunteers, demonstrating the applicability of nES GEMMA for EBC characterization focussing on possibilities and limitations of the instrumentation [2]. Based on our findings, we then continued in a clinical setting characterizing EBC of n=5 lung cancer patient and n=5 control samples, respectively. Despite the low number of donors in the second part of our study we could show differences in nES GEMMA spectra from healthy and patient donors. Although further work needs to be directed towards in-depth characterization of EBC and detected EBC components, we are convinced that EBC analysis via nES GEMMA will be a valuable tool in lung cancer diagnosis in the future. The authors acknowledge funding through an ERASMUS fellowship, through the Austrian Science Fund FWF (P-33546-B) and via an institutional support (RVO:68081715). Part of the study was funded by a SFU MED Forschungsförderungsfond 2023 pilot study.
